Phibro Animal Health Corporation Announces Regulatory Framework Change in Brazil for Antimicrobials

Key Terms

antimicrobials medical

Antimicrobials are drugs and substances that kill or stop the growth of tiny organisms like bacteria, viruses, fungi and parasites — think of them as pesticides for germs. They matter to investors because demand, regulatory approval, resistance trends and public-health policies directly affect sales, research-and-development value and long-term market prospects for companies that make or sell these products.

virginiamycin medical

Virginiamycin is an antibiotic commonly added to livestock feed to prevent or treat bacterial infections and, in some cases, to help animals grow more efficiently; think of it as a medicine mixed into feed to keep animals healthier, like a preventive supplement. It matters to investors because its use is tightly regulated and can affect sales, export access, regulatory risk, reputation, and costs for companies in animal health, feed production, and the food supply chain.

bacitracin medical

An antibiotic ointment used on skin cuts, scrapes and minor wounds to stop or prevent bacterial infection; it’s applied directly where the injury is, like a household first‑aid cream. Investors care because its regulatory approvals, manufacturing quality, supply availability, patent or exclusivity status, and any safety concerns or recalls directly affect sales, costs and legal risk—similar to how shelf placement, labeling and safety issues influence a consumer product’s market value.

veterinary prescription regulatory

A veterinary prescription is a medicine or medical treatment that may only be sold or administered for animals after a licensed veterinarian evaluates the patient and issues an authorization, similar to a doctor’s prescription for people. For investors it matters because prescription status creates regulatory oversight, controlled sales channels, and higher barriers to entry—like a locked gate—that can support steadier pricing, recurring demand for chronic treatments, and clearer paths (or hurdles) for revenue and market access.

digital platform technical

A digital platform is an online system—like a marketplace, app store, or social hub—that connects users, providers, and services so they can interact, buy, sell, share or access content. Investors care because platforms can scale quickly, generate recurring revenue from many users, and become more valuable as more people use them (similar to a town square getting busier and more useful), but they also face risks from competition, regulation and changing user habits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEANECK, N.J.--(BUSINESS WIRE)-- Phibro Animal Health Corporation (Nasdaq: PAHC) today announced expected implementation of a new regulatory framework governing the use of certain antimicrobials in Brazil that have growth promotion indications.

The Brazilian Ministry of Agriculture and Livestock (MAPA) published Ordinance No. 1617 on April 27, 2026, prohibiting the importation, manufacture, marketing and use of performance enhancing feed additives containing antimicrobials classified as important in human or veterinary medicine, including virginiamycin and bacitracin. This regulation brings Brazil into alignment with regulatory approaches adopted in other global markets. This prohibition will come into effect after a transition period of 180 days from the date of the Ordinance, during such times companies and customers may continue to use and sell the products under their current labels.

Phibro is working cooperatively with MAPA and relevant industry associations to support an orderly transition. The Company has been actively engaged with MAPA on new registrations of virginiamycin for therapeutic use in cattle and broiler chickens. These registrations are in the final stages of review and approval by MAPA and are expected during the transition period.

Phibro’s bacitracin product already carries therapeutic claims in Brazil.

Under the new regulatory framework, following the transition period, use of the subject antimicrobials will require a veterinary prescription. To support compliance and operational efficiency, Phibro is making available to the Brazilian market PhibroVet®, a digital platform designed to facilitate the creation, transmission, and management of veterinary prescriptions and prescription history.

Based on the 180 day transition period, the Company expects the regulatory change to have limited impact on its fiscal year 2026 results. Additional information will be provided during the Company’s upcoming earnings call scheduled for May 7, 2026.

About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. The Company strives to be a trusted partner to livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions that help maintain and enhance animal health. For more information, visit www.pahc.com.

Forward-Looking Statements

DISCLOSURE NOTICES

Forward-Looking Statements: This communication contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this communication are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Quarterly Report on Form 10-Q and Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements” and “Risk Factors.” These filings and subsequent filings are available online at www.sec.gov, www.pahc.com, or on request from Phibro.

Internet Posting of Information: We routinely post information that may be important to investors in the “Investors” section of our website at www.pahc.com. We encourage investors and potential investors to consult our website regularly for important information about us.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260427781656/en/

Phibro Animal Health Corporation
Glenn C. David
Chief Financial Officer
+1-201-329-7300
or
investor.relations@pahc.com

Source: Phibro Animal Health Corporation